ClinicalTrials.gg
TerminatedNCT06360757Updated Mar 18, 2025

Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19)

An observational study in SARS-CoV-2 Acute Respiratory Disease, sponsored by QIAGEN Gaithersburg, Inc. Terminated at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by QIAGEN Gaithersburg, Inc (part of QIAGEN) · Observational

How we know

Why this study was terminated
Discontinuation of product line

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
503
Sex
All
01

Study summary

A multicenter study, using prospectively collected, fresh (Category I) and frozen (Category II), residual/leftover nasopharyngeal (NP) swab in UTM/UVT specimens obtained from symptomatic individuals suspected of COVID-19 infection. This study will evaluate the NeuMoDx SARS-CoV-2 Assay's clinical performance on the NeuMoDx 288 and NeuMoDx 96 Molecular Systems.

02

Conditions studied

  • SARS-CoV-2 Acute Respiratory Disease
03

In context

Lead sponsor

QIAGEN Gaithersburg, Inc is the lead sponsor of 27 studies on the registry; 1 is open to participants now.

First submitted after QIAGEN Gaithersburg, Inc became part of QIAGEN.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Symptomatic subjects suspected of COVID-19

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Any de-identified NP swab specimen in transport medium from a symptomatic individual suspected of COVID-19 at the time of collection.
  2. NP swab specimens obtained using a flexible mini-tip flocked swab and collected into 3mL Copan UTM [Cat. No. 305C] or BD UVT [Cat. No. 220531].
  3. Prospective specimens, fresh (Category I) shall be tested within:

    1. (4) hours when held at room temperature, or
    2. (3) days when held at (2 to 8°C), with cold storage starting within (4) hours of collection.
  4. Minimum volume of ≥ 2mL.

Exclusion criteria

Exclusion Criteria:

  1. Required information unable to be obtained from the associated medical chart.
  2. Specimens that remained on-board the NeuMoDx System for > (8) hours prior to processing.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
503 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Diagnostic testNeuMoDx SARS-CoV-2 Assay

    The NeuMoDx™ SARS-CoV-2 Assay is an automated, in vitro nucleic acid amplification test intended for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal (NP) swabs in transport medium obtained from symptomatic individuals suspected of COVID-19 infection. The NeuMoDx SARS-CoV-2 Assay as performed on the NeuMoDx™ 288 Molecular System and NeuMoDx™ 96 Molecular System incorporates automated RNA extraction to isolate target nucleic acids from the specimen and real-time reverse transcription PCR targeting two conserved regions of the SARS-CoV-2 genome.

06

What researchers measure

Primary outcomes

  1. Sensitivity as compared to the comparator method

    Sensitivity ≥ 95% with a lower bound of the two-sided 95% CI \> 90%

    Time frame: Through study completion estimated 9 months

Secondary outcomes

  1. Specificity

    Specificity ≥ 95% with a lower bound of the two-sided 95% CI \> 90%

    Time frame: Through study completion estimated 9 months

07

Study locations

1 site
  • QIAGEN Gaithersburg, Inc
    Manchester, M130BH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jul 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 11, 2024
StartActual
Feb 6, 2024
Primary completionActual
Jul 24, 2024
CompletionActual
Jul 24, 2024
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06360757
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
Feb 6, 2024
Primary completion
Jul 24, 2024
Completion
Jul 24, 2024
Last update
Mar 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion